The analysis demonstrated that patients receiving pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experienced significantly more good days and reduced hospital stays compared to those treated with standard therapy (ST). Specifically, PIPAC patients had a median of 181 good days at six months versus 131 days for ST, and an overall survival median of 11.3 months compared to 5.1 months with ST. Importantly, PIPAC showed no negative impact on health-related quality of life despite its repeated administration.
Journal Article by Waheed MT, Ruel N (…) Raoof M et 8 al. in Ann Surg Oncol
© 2024. The Author(s).